Study Summary: This is a Phase 3 study to see how well a drug called lorundrostat helps lower blood pressure (BP) in people with uncontrolled and resistant hypertension. Hypertension is another word for high blood pressure. "Uncontrolled and resistant" means it's hard to manage even with medications. Lorundrostat is an aldosterone synthase inhibitor, which means it helps block a chemical that can raise blood pressure. People in this study will take lorundrostat along with 2 to 5 other blood pressure medications, including a type called thiazide diuretics.

The study lasts for about 16 weeks, starting with a screening period of 2 weeks, followed by another 2-week period where everyone takes a placebo (inactive pill). Then, the main part of the study lasts 12 weeks, where some people will get lorundrostat and others will get a placebo. After this, participants can choose to join an extra study period with lorundrostat.

• The study is about 16 weeks long, with a chance to join an additional study period.
• You must be at least 18 years old and have specific blood pressure readings to join.
• Pregnant women or those planning to become pregnant cannot participate.